Literature DB >> 12594809

Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system.

Mary Ann C Sabino1, Nancy M Luger, David B Mach, Scott D Rogers, Matthew J Schwei, Patrick W Mantyh.   

Abstract

Pain is the most common presenting symptom in patients with bone cancer and bone cancer pain can be both debilitating and difficult to control fully. To begin to understand the mechanisms involved in the generation and maintenance of bone cancer pain, we implanted 3 well-described murine tumor cell lines, 2472 sarcoma, B16 melanoma and C26 colon adenocarcinoma into the femur of immunocompromised C3H-SCID mice. Although each of the tumor cell lines proliferated and completely filled the intramedullary space of the femur within 3 weeks, the location and extent of bone destruction, the type and severity of the pain behaviors and the neurochemical reorganization of the spinal cord was unique to each tumor cell line injected. These data suggest that bone cancer pain is not caused by a single factor such as increased pressure induced by intramedullary tumor growth, but rather that multiple factors are involved in generating and maintaining bone cancer pain. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12594809     DOI: 10.1002/ijc.10999

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  40 in total

Review 1.  Bone cancer pain.

Authors:  Juan Miguel Jimenez-Andrade; William G Mantyh; Aaron P Bloom; Alice S Ferng; Christopher P Geffre; Patrick W Mantyh
Journal:  Ann N Y Acad Sci       Date:  2010-06       Impact factor: 5.691

Review 2.  Mechanism of cancer pain.

Authors:  Brian L Schmidt; Darryl T Hamamoto; Donald A Simone; George L Wilcox
Journal:  Mol Interv       Date:  2010-06

3.  WNT signaling underlies the pathogenesis of neuropathic pain in rodents.

Authors:  Yan-Kai Zhang; Zhi-Jiang Huang; Su Liu; Yue-Peng Liu; Angela A Song; Xue-Jun Song
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808

4.  Behavioral characteristics of a mouse model of cancer pain.

Authors:  Bae Hwan Lee; Jinsil Seong; Un Jeng Kim; Ran Won; Jiyoung Kim
Journal:  Yonsei Med J       Date:  2005-04-30       Impact factor: 2.759

5.  Bilateral downregulation of Nav1.8 in dorsal root ganglia of rats with bone cancer pain induced by inoculation with Walker 256 breast tumor cells.

Authors:  Xue-Rong Miao; Xiao-Fei Gao; Jing-Xiang Wu; Zhi-Jie Lu; Zhang-Xiang Huang; Xiao-Qing Li; Cheng He; Wei-Feng Yu
Journal:  BMC Cancer       Date:  2010-05-20       Impact factor: 4.430

6.  Behavioral, medical imaging and histopathological features of a new rat model of bone cancer pain.

Authors:  Louis Doré-Savard; Valérie Otis; Karine Belleville; Myriam Lemire; Mélanie Archambault; Luc Tremblay; Jean-François Beaudoin; Nicolas Beaudet; Roger Lecomte; Martin Lepage; Louis Gendron; Philippe Sarret
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

7.  Endothelin-A receptor antagonism attenuates carcinoma-induced pain through opioids in mice.

Authors:  Phuong N Quang; Brian L Schmidt
Journal:  J Pain       Date:  2010-01-13       Impact factor: 5.820

8.  Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis.

Authors:  Qian Yin; Li Tang; Kaimin Cai; Rong Tong; Rachel Sternberg; Xujuan Yang; Lawrence W Dobrucki; Luke B Borst; Debra Kamstock; Ziyuan Song; William G Helferich; Jianjun Cheng; Timothy M Fan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-25       Impact factor: 11.205

9.  Intrathecal administration of Resolvin D1 and E1 decreases hyperalgesia in mice with bone cancer pain: Involvement of endocannabinoid signaling.

Authors:  Iryna A Khasabova; Mikhail Y Golovko; Svetlana A Golovko; Donald A Simone; Sergey G Khasabov
Journal:  Prostaglandins Other Lipid Mediat       Date:  2020-07-31       Impact factor: 3.072

Review 10.  Animal models of cancer pain.

Authors:  Cholawat Pacharinsak; Alvin Beitz
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.